Selective cyclooxygenase inhibition: its role in pain and anaesthesia

Biomedicine and Pharmacotherapy

Volumn 60, Issue 7, 2006, Pages 323-328

  Langford, R M ^a   Mehta, V ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Complications; Cyclooxygenase; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; KETOROLAC; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SODIUM ION; VALDECOXIB;

ACUTE HEART INFARCTION; ADENOMATOUS POLYP; ANESTHESIA; ANESTHESIA MECHANISM; ARTHRITIS; ARTICLE; ASTHMA; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; FRACTURE HEALING; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEART ARREST; HEART INFARCTION; HUMAN; HYPERALGESIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG EMBOLISM; NERVE CELL PLASTICITY; PEPTIC ULCER; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; SODIUM EXCRETION; STROKE; SUDDEN DEATH; THROMBOCYTE FUNCTION; WOUND COMPLICATION;

BLOOD PLATELETS; CYCLOOXYGENASE INHIBITORS; FRACTURE HEALING; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY; NEURONS; PAIN;

EID: 33747883681     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.06.017     Document Type: Article

References (36)

1. 2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurons via cyclic AMP-protein kinase A cascade. J. Physiol. 495 (1996) 429-440
2. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nat. New Biol. 231 25 (1971) 232-235
3. Blower A.L., Brooks A., Fenn G.C., Hill A., Pearce M.Y., Morant S., and Bardhan K.D. Aliment. Pharmacol. Ther. 11 (1997) 283-291
4. Needleman P., and Isakson P.C. The discovery and function of COX-2. J. Rheumatol. 24 Suppl 49 (1997) 6-8
5. Food and Drug Administration. FDA announces series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs) (2005), FDA, Rockville, MD
6. EMEA Press release: European Medicines Agency concludes action on COX-2 inhibitors EMEA Doc. Ref. EMEA/207766/2005.
7. Nussmeier N.A., Whelton A., Brown M.T., Langford R.M., Joshi G., and Verburg K.M. Safety of parecoxib and valdecoxib in the treatment of pain following coronary artery bypass surgery. N. Engl. J. Med. 352 (2005) 1081-1091
8. Ott E., Nussmeier N.A., Duke P.C., Fenek R.O., Alston R.P., Snabes M.C., Hubbard R.C., Hsu P.H., Saidman L.J., and Mangano D.T. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 125 (2003) 1481-1492
9. Nussmeier N.A., Whelton A., Brown M.T., Langford R.M., Joshi G., Singla N.K., Boye M.E., and Verburg K.M. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology 104 3 (2006) 518-526
10. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352 (2005) 1092-1102
11. Graham D.J., Campen D., Hiu R., Chatham C., Levy G., Shoor S., and Ray W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
12. Silverstein F.E., Faich G., Goldstein J.I., Simon L.S., Pincus T., Whelton A., Makkuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., and Geiss G.S. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. JAMA 284 (2000) 1247-1255
13. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352 (2005) 1071-1080
14. Bombardier C., Laine I., Reicin A., Shapiro D., Burgos V.R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hoekberg M.C., Kvien T.K., and Schmitzer T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343 21 (2000) 1520-1528
15. National Institutes of Health. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial (2004), NIH, Bethesda, MD
16. Hawkey C.J. COX-2 inhibitors. Lancet 353 (1999) 307-314
17. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., Gimona A., and Hawkey C.J. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 364 (2004) 665-674
18. Farkouh M.E., Kirshner H., Harrington R.A., Ruland S., Verheught F.W.A., Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., Gimona A., Hawwkey C.J., and Chesebro J.H. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet 364 (2004) 675-684
19. Komhoff M., Grone H.J., Klein T., Seyberth H.W., and Nusing R.M. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am. J. Physiol. 272 4 Pt 2 (1997) F460-F468
20. Catella-Lawson F., McAdam B., Morrison B.W., Kapoor S., Kujuber D., Antas L., Lasseter K.E., Quan H., Gertz B.J., and Fitzgerald G.A. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289 (1999) 735-741
21. Harris R.C., McKanna J.A., Akai Y., Jacobson H.R., Dubois R.N., and Breyer M.D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases salt restriction. J. Clin. Invest. 94 (1994) 2504-2510
22. Whelton A., Fort J.G., Puma J.A., Normandin D., Bello A.E., and Verburg K.M. Cyclooxygenase-2- specific inhibitors and cardiorenal function: a randomized controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 8 (2001) 85-95
23. Rossat J., Maillard M., Nussberger J., Brunner H.R., and Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther. 66 1 (1999) 76-84
24. Woessner K.M., Simon R.A., and Stevenson D.D. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 46 8 (2002) 2201-2206
25. Gyllfors P., Bochenek G., Overholt J., Drupka D., Kumlin M., Sheller J., Nizamkowska E., Isakson P.C., Mejza F., Lefkowith J.B., Dahlen S.E., Szczeklik A., Murray J.J., and Dahlen B. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2- selective analgesic drug celecoxib. J. Allergy Clin. Immunol. 111 5 (2003) 1116-1121
26. Noveck R.J., Laurent A., Kuss M., Talwalker S., and Hubbard R.C. Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals. Clin. Drug Invest 21 7 (2001) 465-476
27. Ketorolac data sheet ABPI compendium 2004.
28. Moiniche S., Romsing J., Dahl J.B., and Tramer M.R. Nonsteroidal anti-inflammatory drugs and the risk of operative site bleeding after tonsillectomy: a quantitative systematic review. Anesth. Analg. 96 1 (2003) 68-77
29. Tornkvist H., Lindhom T.S., Netz P., Stromberg L., and Lindholm T.C. Effect of ibuprofen and indomethacin on bone metabolism reflected in bone strength. Clin. Orthop. Relat. Res. 187 (1984) 255-259
30. Glassman S.D., Rose S.M., Dimar J.R., Puno R.H., Campbell M.J., and Johnson J.R. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 23 (1998) 834-838
31. Giannoudis P.V., MacDonald D.A., Matthews S.J., Smith R.M., Furlong A.J., and De Boer P. Non-union of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J. Bone Joint Surg. Br. 82 (2000) 655-658
32. Reuben SS, Rizvi A, Steinberg RB, Maciolek H. The effect of NSAIDs on spinal fusion. 27th Annual Spring Meeting and Workshops 2002; PD-16.
33. Reuben SS. Considerations in the use of COX2 inhibitors in spinal fusion surgery: in response. Anaesthesia and Analgesia 4 93 (2001) 803-804
34. Samad T.A., Morre K.A., Sapirstein A., Billet S., Allchrone A., Poole S., Bonventre J.V., and Woolf C.J. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410 6827 (2001) 471-475
35. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., and Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA 95 (1998) 13313-13318
36. Hyllested M., Jones S., Pederson J.L., and Kehlet H. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br. J. Anaesth. 88 (2002) 199-214